Peer-reviewed veterinary case report
New manganese drug tested for helping treat lymphoma in dogs
By M. Boss et al.·Published in Cancer Chemotherapy and Pharmacology·2017·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma (a type of cancer) was studied to see how a new drug called Mn(III) meso-tetrakis (N-n-butoxyetylpyridium-2-yl) porphyrin (MnBuOE) could help in their treatment. The drug was given at a specific dose three times a week for a few weeks, but some dogs experienced an allergic reaction and increased heart rate after the injection. The researchers found that the drug built up in the lymph nodes, which is promising for its use in treating lymphoma. This information could help improve treatment plans and reduce side effects for dogs with this condition.
People also search for: dog lymphoma treatment · manganese porphyrin for dogs · dog cancer drug side effects
Abstract
PurposeManganese porphyrins are redox-active drugs and superoxide dismutase mimics, which have been shown to chemosensitize lymphoma, a cancer which frequently occurs in dogs. This study aimed to identify critical information regarding the pharmacokinetics and toxicity of Mn(III) meso-tetrakis (N-n-butoxyetylpyridium-2-yl) porphyrin, (MnTnBuOE-2-PyP5+, MnBuOE) in dogs as a prelude to a clinical trial in canine lymphoma patients.MethodsA single-dose pharmacokinetic (PK) study in normal dogs was performed to determine the plasma half-life (t1/2) of MnBuOE. A dose reduction study was performed to establish the maximum tolerated dose (MTD) of MnBuOE. The safety and PK of a multi-dosing protocol was assessed.ResultsPeak plasma drug concentration occurred 30 min post-injection. The t1/2 was defined as 7 h. MnBuOE induced an anaphylactic reaction and prolonged tachycardia. The MTD was defined as 0.25 mg/kg. The dogs were given MTD 3×/week for 2–3 weeks. The highest recorded tissue drug levels were in the lymph nodes (4–6 μM), followed by kidney and liver (2.5, 2.0 uM, respectively).ConclusionsWe obtained critical information regarding the PK and toxicity of MnBuOE in dogs. The acute drug reaction and tachycardia post-injection have not been described in other species and may be specific to canines. The high tissue drug levels in lymph nodes have not been previously reported. MnBuOE accumulation in lymph nodes has important implications for the utility of adjuvant MnBuOE to treat lymphoma. With MnBuOE lymph node accumulation, reduction in the dose and/or administration frequency could be possible, leading to reduced toxicity.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/28685347